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Bone Morphogenesis and Modeling: Minireview
Soluble Signals Sculpt
Osteosomes in the Solid State
A. H. Reddi The newly formed bone, both cortical and cancellous,
consists of extracellular matrix (Piez and Reddi, 1984)Center for Tissue Regeneration and Repair
and Department of Orthopaedic Surgery with a constellation of constituents (Table 1) that is min-
eralized. Bone is akin to reinforced concrete. The fibrillarUniversity of California, Davis
Sacramento, California 95817 collagens with associated supramolecular assembly of
a cornucopia of noncollagenous proteins (Table 1) are
encrusted with the common geomineral hydroxyapatite
with the generic structure of 3 Ca3(PO4)2´Ca(OH)2. The
hydroxyapatite in vivo is associated with carbonate, flu-It is common knowledge that bone, like all matter, is in
both a soluble and a solid state. There is a continuum oride, magnesium, and citrate. The bone mineral has
profound avidity for ``bone-seeking'' substances suchbetween the soluble and solid states that is regulated by
signals insolution interacting with insoluble extracellular as tetracyclines and bisphosphonates (during peace
time, thanks to physicians) and uranium and plutoniummatrix. A beautiful example of the interface of signals
and extracellular matrix is the human skeleton. The skel- (during war, thanks to generals!). This property of min-
eral-associated tetracyclines allows one to mark andeton evolved for several purposes: for locomotion to
forage for food in the wild; for copulation to procreate determine bone apposition rates using various fluoro-
chromes. The bone mineral is opaque to X-rays, permit-the species and maintain the gene pool; for protection
of vital internal organs including hematopoietic marrow; ting orthopedic surgeons and radiologists to image the
skeleton. How is the bone modeled in the embryo andand as a reservoir of vital ions such as calcium and
phosphate and of trace elements such as magnesium remodeled in the adult? This question is addressed by
an exciting report in this issue of Cell by Simonet et al.and zinc with critical roles in metabolism including DNA
synthesis, replication, repair, transcriptional and transla- describing a novel secreted member of theTNF receptor
superfamily increasing bone density and is the focus oftional regulation, and finally (the inevitable) cell death
and apoptosis. this minireview.
The formation of bone by osteoblasts, and its model-Bone can develop by one of two routes. Mesenchymal
cells can differentiate directly to bone, as occurs in the ing in a growing child and remodeling in adults by osteo-
clasts, is a closely integrated homeostatic system.Whenflat bones of the craniofacial skeleton; this process
is termed intramembranous ossification. Alternatively, thinking about the molecular cell biology of bone model-
ing and maintenance, it is important to think in termscartilage can provide a blueprint or template for bone
morphogenesis, as occurs in the majority of the over of the smallest quantum unit of bone that has all the
ingredients of bone (extracellular matrix, bone matrix200 bones in the human skeleton. The cartilage blueprint
is ephemeral and is replaced by bone in a process proteins, and mineralized matrix; see Table 1). I propose
the term ``osteosome'' to signify this smallest quantumtermed endochondral ossification (Reddi, 1981). Bone
is also continuously modeled during growth and devel- unit. The steady state mineral density of the osteosome
results from the the balance of anabolic osteoblasts andopment and remodeled throughout the life of the organ-
ism in response to physical and chemical signals. The catabolic osteoclasts. Osteoclasts are multinucleated
and are present in both cortical and cancellous bone.physical signals include, but are not limited to, gravity,
electricity, magnetism, and ultrasound. The osteoclasts create a microenvironment by sealing
off the cell membrane and the area of resorption. TheBones are a superb example of design architecture
and engineering. They consist of cortical or compact adhesion and sealing are mediated by integrins (Hynes,
1992). The osteoclast is a polarized cell with vectorialbone and cancellous or trabecular bone. The outer corti-
cal and inner trabecular bone network permits mechani- discharge of H1 ions to disolve minerals and enzymes
such as proteases, collagenases, and cathespins to de-cal function and adaptation to changing mechanical
environment and signals. Osteoporosis is a systemic grade the extracellular matrix osteosome (Baron, 1993).
Local cytokines and systemic hormones regulate osteo-skeletal disease of low bone mass, loss of the network
of trabeculae, and deterioration of microarchitecture in clast function. The hormones are parathyroid hormone
(PTH), calcitonin (CT), and vitamin D3. The cytokinesbone trabeculae especially in postmenopausal women
(Riggs and Melton, 1992). In developing bone, osteo- include interleukins (IL-1, IL-4, IL-6, and IL-11) and tumor
necrosis factors (TNFa and TNFb). TNF is a term coinedblasts of mesenchymal lineage initially form woven
bone that is subsequently modeled by osteoclastsof the by Lloyd Old and colleagues. It was recognized as the
cachectin involved in cachexia (or wasting syndrome)hematopoietic monocyte-macrophage lineage (Marks,
1989), leading to the formation of lamellar bone with by Cerami and Beutler. TNFa increases bone resorption
(Bertolini et al., 1986). The molecular cloning of TNFsits characteristic concentric rings with a central blood
vessel. The osteocytes and osteoblasts in the bone form spawned an unprecedented period of research activity
including identification of receptors. Two distinct buta syncytium by gap junctions and connecting canalicular
cell processes (Vukicevic et al., 1990). The primordial structurally homologous receptors for TNF, p75 and p55,
were identified. As many as a dozen receptors are nowsignals for the lineage of bone-forming osteoblasts are
the family of bone morphogenetic proteins (Reddi, known including nerve growth factor receptor, CD27,
CD30, CD40, and Fas antigen (Smith et al., 1994; Aderka,1997).
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Table 1. Macromolecules in the Osteosome, the Quantum Unit developing chondrogenic foci and in developing cranio-
of the Extracellular Matrix (ECM) of Bone facial bones.
Next, in order to assess its in vivo function, the novelConstituent Function
rat TNF receptor±related protein was expressed underCollagens
the control of human apolipoprotein E gene promoterType I collagen Principal ECM
and associated liver-specific enhancer in transgenic(2 a1 chains) Component
(1 a2 chain) Supramolecular assembly mice (Simonet et al., 1997). The radiographs revealed
Type III, V collagens Minor collagens higher bone density. However, there was also spleno-
Proteoglycans megaly due to occulusion of the bone marrow cavities,
Versican Occupies space due to
which resulted in compensatory extramedulary hemato-``extended'' conformation
poiesis. This increase in bone density was shown to beBiglycan Binds collagen
due to a decrease in the tartarate-resistant acid phos-Decorin Binds to TGFb
Hyaluronan Interactive with proteoglycan phatase (TRAP)±positive osteoclasts. Targeted disrup-
Leucine-rich proteins tion of the gene for TRAP also disrupts endochondral
Osteoadherin Cell attachment ossification and results in mild osteopetrosis (Hyman et
Osteoglycin TGFb/BMP binding
al., 1996). Simonet et al. (1997) call this protein osteopro-Noncollagenous proteins
tegerin (OPG) because it protects bone from resorption.Osteocalcin Remodeling
Direct experiments demonstrated that recombinant os-Osteonectin/SPARC Links mineral to matrix
Osteopontin Cell adhesion teoprotegerin inhibited invitro osteoclastdifferentiation.
Fibronectin Cell adhesion The amino-terminal domain of OPG is the business-
Vitronectin Cell attachment end of the molecule with respect to restriction of the
Thrombospondin Multifunctional cell adhesion
osteoclast lineage. Recombinant OPG increases bonemodulator
density and protects rats against ovariectomy-inducedBone sialoprotein Modulator of mineralization
bone loss and deficit. The human gene is localized toBone-associated Binds calcium
glycoprotein-75 chromosome 8q23±24.
Fibrillin Assembly of elastic fiber Many questions still need to be addressed. What is
Mineral the interacting partner ligand to OPG? How and where
Hydroxyapatite Located in and on ``hole'' zones
does OPG act to restrict and to inhibit the osteoclast3 Ca3(PO4)2´Ca(OH)2 in collagen microfibrils
lineage? What are the relative roles of OPG in protectingas plates/needles
cortical and cancellous bone? How does osteoproteg-
erin protect the osteosome, the smallest supramolecular
unit of bone (Table 1), the quantum unit of bone, from
1996). Soluble versions of these receptors bind cognate resorption? I predict the answers should arrive in time
ligands and influence bioavailability. Certain soluble for Christmas/Hanukkah as a gift from Amgen. Osteo-
TNFRs are elevated in disease states such as lupus and protegerin can be added to c-Src, c-Fos, and m-Csf,
rheumatoid arthritis. as another regulator of osteoclast differentiation and
The identification of novel regulators and signaling function.
molecules has required approaches such as expression Bisphosphonates are structural analogs of pyrophos-
cloning, subtractive hybridization, candidate molecules, phate that contain phosphorus-carbon-phosphorus
RT±PCR of Drosophila morphogens, and the use of (P-C-P) bonds instead of phosphorus-oxygen-phospho-
expressed sequence tags (ESTs). The present identi- rus bonds (Fleisch, 1997). Bisphosphonates bind with
fication of a novel soluble TNF receptor increasing high affinity to bone mineral crystals and inhibit the dis-
bone density, by decreasing bone resorption, has been solution of minerals. Furthermore the P-C-P bonds in
achieved by researchers at Amgen based on ESTs (Si- bisphosphonates are resistant to enzymatic hydrolysis
monet et al., 1997). The authors of this report initially by acid and alkaline phosphatases or pyrophosphatase.
identified a novel member of the TNF receptor (TNFR) These properties explain the fact that bisphosphonates
family from the fetal rat intestine. The novel cDNA en- act as potent inhibitors of bone resorption in vivo. As
codes a 401±amino acid protein and appears to be a such, they have been extensively studied for possible
secreted glycoprotein with a leader sequence. The therapeutic application in Paget's disease of bone, hy-
amino half of the sequence is related closely to TNFR-2 percalcemia of malignancy, and osteolytic metastases
and CD40.The protein,however, lackssequence homol- (Fleisch, 1997). Also, ovariectomy-induced bone loss
ogies to known TNFRs in the carboxy-terminal half. can be prevented by bisphosphonates, suggesting ther-
Pulse-chase experiments demonstrated the dimeric na- apeutic use in osteoporosis. Because osteoprotegerin
ture of the secreted protein of a molecular mass of 110 also blocks bone resorption in vivo, it is conceivable
kDa and is a glycoprotein. It is noteworthy that it is that osteoprotegerin may also have a clinical utility in
expressed in intestine, liver, kidney, lung, and calvaria. osteoporosis. Only time and more clinical studies will
Calcium and phosphate transport and homeostasis is tell if osteoprotegerin will be another winner, such as
a collaborative venture of intestine, kidney, and bone. erythropoietin, for Amgen.
It is interesting to note that this novel gene product is
highly expressed by the same triad of tissues. It is likely Selected Reading
that there are both local and systemic functions for this
Aderka, D. (1996). Cytokine Growth Factor Rev. 7, 231±240.protein. In humans and mouse, it is also detected in the
placenta. In situ hybridization revealed localization in Baron, R. (1993). In Physiology and Pharmacology of Bone, G.R.
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